Cerebrospinal fluid ctDNA as a prognostic and disease-activity biomarker in leptomeningeal metastases: systematic review, meta-analysis, and implications for CSF-guided care
Journal of Neuro-Oncology · 2026-04 · 177 (2)
DOI: 10.1007/s11060-026-05520-8 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Neuro-Oncology, online erschienen am 26.03.2026. Verfasst von Baradwaj Simha Sankar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Albany Medical College, Albany, NY, USA. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Biomarkers, Tumor, Meningeal Neoplasms, Meningeal Carcinomatosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 60 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Leptomeningeal disease (LMD) is a devastating complication of advanced solid tumors with limited prognostic and response-assessment tools. Because LMD molecular evolution is frequently compartmentalized behind CNS barriers, cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) may provide CNS-specific molecular readouts of disease activity. We evaluated whether baseline CSF ctDNA profiles and longitudinal ctDNA kinetics associate with survival in LMD. METHODS: We performed a systematic review and meta-analysis (PROSPERO CRD420251068543) of Embase, PubMed, Cochrane CENTRAL, WHO ICTRP, ClinicalTrials.gov, Europe PMC, and Web of Science from inception through June 2025. Eligible studies included adults with solid-tumor LMD undergoing anti-cancer therapy with CSF ctDNA assessed at baseline and/or serially and reported associations with overall survival (OS) and/or progression-free survival (PFS). Random-effects models pooled hazard ratios (HRs). Longitudinal studies were analyzed separately due to limited availability. RESULTS: Fourteen studies (n = 963) evaluated baseline CSF ctDNA and two studies (n = 26) evaluated longitudinal kinetics. Adverse (non-reference) baseline ctDNA status (e.g., EGFR mutation positive vs. negative) was associated with inferior OS (pooled HR 2.40, 95% CI 1.73-3.33; I²=36.6%) and PFS (pooled HR 2.45, 95% CI 1.36-4.44; I²=15.5%). Longitudinally, increasing CSF ctDNA variant allele fraction was associated with worse OS (pooled HR 4.11, 95% CI 1.25-13.48; I²=8.5%). Across longitudinal reports, serial CSF ctDNA measurements tracked progression and response. CONCLUSION: Baseline and serial CSF ctDNA measurements are associated with survival outcomes in LMD and may complement clinical and radiographic assessment. These findings support prospective, standardized, multi-timepoint CSF ctDNA studies in LMD and warrant CSF-access-enabled monitoring to inform therapeutic adaptation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Albany Medical College, Albany, NY, USA.
- University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA.
- Northwell, New Hyde Park, NY, USA.
- Department of Neurosurgery, Lenox Hill Hospital, New York, NY, USA.
- Northwell, New Hyde Park, NY, USA. rdamico8@northwell.edu.
- Department of Neurosurgery, Lenox Hill Hospital, New York, NY, USA. rdamico8@northwell.edu.
Zitieren
APA
Sankar, B. S., Johnson, D., Boasiako, P. A., Vargas, L. O., Syed, S., Padova, A., & D'Amico, R. S. (2026). Cerebrospinal fluid ctDNA as a prognostic and disease-activity biomarker in leptomeningeal metastases: systematic review, meta-analysis, and implications for CSF-guided care. Journal of Neuro-Oncology, 177(2). https://doi.org/10.1007/s11060-026-05520-8
Vancouver
Sankar BS, Johnson D, Boasiako PA, Vargas LO, Syed S, Padova A, et al. Cerebrospinal fluid ctDNA as a prognostic and disease-activity biomarker in leptomeningeal metastases: systematic review, meta-analysis, and implications for CSF-guided care. Journal of Neuro-Oncology. 2026;177(2). doi:10.1007/s11060-026-05520-8
BibTeX
@article{Sankar2026,
author = {Sankar, Baradwaj Simha and Johnson, Drew and Boasiako, Paul Antwi and Vargas, Luis O and Syed, Shoaib and Padova, Audrey and D'Amico, Randy S},
title = {Cerebrospinal fluid ctDNA as a prognostic and disease-activity biomarker in leptomeningeal metastases: systematic review, meta-analysis, and implications for CSF-guided care},
journal = {Journal of Neuro-Oncology},
year = {2026},
volume = {177},
number = {2},
doi = {10.1007/s11060-026-05520-8}
}
EUVIMED